

## PHARMACY POLICY STATEMENT

### Marketplace

<b>DRUG NAME</b>	<b>Inhaled Prostacyclins for Pulmonary Arterial Hypertension: Tyvaso, Yutrepia (treprostinil) and Ventavis (iloprost)</b>
<b>BENEFIT TYPE</b>	Pharmacy
<b>STATUS</b>	Prior Authorization Required

Pulmonary Arterial Hypertension (PAH) is a rare but serious condition characterized by elevated pulmonary arterial resistance. Ventavis, Yutrepia and Tyvaso are approved for the treatment of PAH World Health Organization (WHO) Group 1. Ventavis is approved to increase exercise tolerance, improve symptoms (NYHA Class), and delay deterioration for PAH. Tyvaso and Yutrepia are indicated to improve exercise ability for adults with PAH. They are also indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

Inhaled Prostacyclins will be considered for coverage when the following criteria are met:

#### Pulmonary Arterial Hypertension [WHO Group 1]

For **initial** authorization:

1. Member is at least 18 years of age or older; AND
2. Medication must be prescribed by or in consultation with a cardiologist or pulmonologist; AND
3. Member must have a diagnosis of WHO Group 1 PAH confirmed by right heart catheterization; AND
4. Member must have documentation of **ONE** of the following:
  - a) Patient had an acute response to vasodilator testing AND has tried a calcium channel blocker (CCB) for at least 3 months;
  - b) Patient did not have a response to vasodilator testing;
  - c) Patient cannot undergo vasodilator testing;
  - d) Patient cannot take CCB therapy; AND
5. Member has tried and failed **ONE** of the following oral medications: phosphodiesterase type 5 inhibitor (ie. Sildenafil, Tadalafil), endothelin receptor antagonist (ie. Ambrisentan, Bosentan, Macitentan), or Soluble Guanylate Cyclase Stimulator (ie. Adempas); OR
6. Member has WHO functional class III symptoms with rapid progression of disease (see appendix); OR
7. Member has WHO functional class IV symptoms (see appendix); AND
8. For Tyvaso DPI: Member has tried and failed a 90-day trial of Tyvaso nebulizer solution.
9. **Dosage allowed/Quantity limit:**

Tyvaso: Initiate 3 breaths (18 mcg) per treatment session; Titrate to target maintenance dosage of 9 to 12 breaths per treatment session, 4 times daily. Quantity Limit: 288 mcg/day.

Tyvaso DPI: Initiate one cartridge (16 mcg) per treatment session; Titrate to target maintenance dosage of 48 mcg to 64 mcg per treatment session, 4 times daily. Quantity Limit: 256 mcg/day.

Ventavis: Initiate 2.5 mcg per treatment session; Titrate to target maintenance dose of 6 to 9 doses (inhalations) per day (minimum of 2 hours between doses during waking hours). Quantity Limit: 45 mcg/day.

Yutrepia: If patient is naive to treprostinil, initiate 26.5 mcg 3 to 5 times per day in 2 breaths based on response. If patient is transitioning from treprostinil inhalation solution (Tyvaso or Tyvaso DPI), dose per PI. Quantity limit: 848 mcg/day.

***If all the above requirements are met, the medication will be approved for 6 months.***

For **reauthorization**:

1. Member has documentation of improvement in signs and symptoms of disease as evidenced by at least **ONE** of the following:
  - a) Stabilization or improvement in functional class symptoms or quality of life;
  - b) Stabilization or improvement in 6MWD (6-minute walk distance).

***If all the above requirements are met, the medication will be approved for an additional 12 months.***

## **Pulmonary Hypertension Associated With Interstitial Lung Disease [WHO Group 3] – Tyvaso and Yutrepia Only**

For **initial** authorization:

1. Member is at least 18 years of age or older; AND
2. Medication must be prescribed by or in consultation with a cardiologist or pulmonologist; AND
3. Member must have a diagnosis of WHO Group 3 PH-ILD confirmed by right heart catheterization; AND
4. Member has evidence of diffuse parenchymal lung disease on computed tomography (CT) imaging of the chest; AND
5. For **Tyvaso DPI**: Member has tried and failed a 90-day trial of Tyvaso nebulizer solution.
6. **Dosage allowed/Quantity limit:**

**Tyvaso**: Initiate 3 breaths (18 mcg) per treatment session; Titrate to target maintenance dosage of 9 to 12 breaths per treatment session, 4 times daily. Quantity Limit: 288 mcg/day.

**Tyvaso DPI**: Initiate one cartridge (16 mcg) per treatment session; Titrate to target maintenance dosage of 48 mcg to 64 mcg per treatment session, 4 times daily. Quantity Limit: 45 mcg/day.

**Yutrepia**: If patient is naive to treprostinil, initiate 26.5 mcg 3 to 5 times per day in 2 breaths based on response. If patient is transitioning from treprostinil inhalation solution (Tyvaso or Tyvaso DPI), dose per PI. Quantity limit: 848 mcg/day.

***If all the above requirements are met, the medication will be approved for 6 months.***

For **reauthorization**:

1. Member has documentation of improvement in signs and symptoms of disease as evidenced by at least **ONE** of the following:
  - a) Stabilization or improvement in functional class symptoms or quality of life;
  - b) Stabilization or improvement in 6MWD (6-minute walk distance).

***If all the above requirements are met, the medication will be approved for an additional 12 months.***

**CareSource considers Inhaled Prostacyclins not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**

DATE	ACTION/DESCRIPTION
06/15/2011	Pulmonary Arterial Hypertension policy creation.
05/13/2014	Combined all PAH agents into one policy
07/09/2015	Revised guidelines for therapy aligning with CMS
08/18/2015	Revised guidelines to include diagnosis criteria
10/13/2021	Separated PAH agents by drug class; Updated guidelines; Added provider specialty; Added PH-ILD; WHO Group 3 indication for Tyvaso

<b>07/08/2022</b>	Added new Tyvaso DPI formulation to dosing instructions; Added a 90-day trial of Tyvaso nebulizer solution prior to Tyvaso DPI; Updated references
<b>05/04/2023</b>	Added references; added quantity limits; updated trials to exclude WHO FC III with rapid progression and IV.
<b>04/30/2024</b>	Updated references; removed PAH diagnosis from appendix.
<b>06/12/2025</b>	Updated references; added Yutrepia to policy including dosing and quantity limit

## Appendix:

World Health Organization Functional Assessment Classification	
<b>Class I</b>	Patients without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.
<b>Class II</b>	Patients with slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
<b>Class III</b>	Patients with marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope.
<b>Class IV</b>	Patients with inability to carry out any physical activity without symptoms. These patients manifest signs of right-heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

New York Heart Association Functional Classification	
<b>Class 1</b>	Cardiac Disease, but no symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs, etc.
<b>Class 2</b>	Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
<b>Class 3</b>	Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest.
<b>Class 4</b>	Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients

## References:

1. Tyvaso [package insert]. Research Triangle Park, NC: United Therapeutics Corp; 2022.
2. Tyvaso DPI [package insert]. Research Triangle Park, NC: United Therapeutics Corp; 2023.
3. Yutrepia [package insert]. Liquidia Technologies, Inc.; 2025.
4. Ventavis [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; 2022.
5. Coons, J.C., Pogue, K., Kolodziej, A.R. et al. Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. *Curr Cardiol Rep.* 2019; 21(141)
6. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report [published correction appears in Chest. 2021 Jan;159(1):457]. *Chest.* 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030
7. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J.* 2023;61(1):2200879. Published 2023 Jan 6. doi:10.1183/13993003.00879-2022
8. Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. *N Engl J Med.* 2021;384(4):325-334. doi:10.1056/NEJMoa2008470
9. Dhont S, Zwaenepoel B, Vandecasteele E, Brusselle G, De Pauw M. Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need. *ERJ Open Res.* 2022;8(4):00272-2022. Published 2022 Nov 14. doi:10.1183/23120541.00272-2022
10. Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. *Eur Respir J.* 2024;64(4):2401325. Published 2024 Oct 31. doi:10.1183/13993003.01325-2024



Effective date: 01/01/2026  
Revised date: 06/12/2025